Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Debt / NOTE 3.250%11/0
-
Unit price / market price
-
$1.02
-
Total 13F principal
-
$218,794,473
-
Principal change
-
-$11,020,527
-
Total reported value
-
$223,386,639
-
Number of holders
-
21
-
Value change
-
-$11,047,671
-
Number of buys
-
3
-
Number of sells
-
8
Institutional Holders of THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 as of Q1 2021
As of 31 Mar 2021 THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 had 21 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $218,794,473 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included CITADEL ADVISORS LLC, Farallon Capital Management, L.L.C., BAUPOST GROUP LLC/MA, WOLVERINE ASSET MANAGEMENT LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, Shaolin Capital Management LLC, OAKTREE CAPITAL MANAGEMENT LP, TENOR CAPITAL MANAGEMENT Co., L.P., ZAZOVE ASSOCIATES LLC, and MORGAN STANLEY.
This table shows 21 bond principal holders of the security as of 31 Mar 2021.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.